Printify
Tumbler 20oz (Purple Bokeh)
Tumbler 20oz (Purple Bokeh)
Couldn't load pickup availability
Enjoy your favorite drinks with durability and purpose using the Endurance Support Tumbler. Designed for daily use, this 20oz tumbler features double-wall insulation to keep beverages hot or cold for hours, making it perfect for your on-the-go lifestyle. Crafted from sturdy stainless steel with a glossy finish, it’s both durable and dishwasher safe for easy cleanup. The clear push-on lid with a rubber gasket ensures a secure fit to prevent spills.
Beyond keeping you refreshed, this tumbler supports a vital cause. 40% of all revenue from the Endurance Support Tumbler goes to Sky Foundation, a non-profit that funds pancreatic cancer research, so every sip contributes to positive change.
- 20oz capacity for ample hydration
- Stainless steel body with plastic and rubber lid for durability
- Double-wall vacuum insulation to keep drinks hot or cold
- Dishwasher safe for convenience
- Glossy finish and rounded corners for a sleek look
Note: Drink to health and hope with a tumbler that supports pancreatic cancer research.
Share



Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...